Clinical Trials in China / NCT07600983

Recruiting Phase 1/2

Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)

NCT07600983 · tracked via the Priya Life Science China tracker

Sponsor

CanSino Biologics Inc.

Phase

Phase 1/2

Started

2026-05-24

Last updated

2026-08-05

Condition(s) studied

Streptococcus Pneumoniae Infection

Investigational drug(s) / intervention(s)

24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (referred to as PCV24) (dose M)PCV24 vaccine (dose H)PCV24 vaccine (dose M)23-valent pneumococcal polysaccharide vaccine (referred to as PPV23)PCV24 vaccine (dose M)13-valent pneumococcal polysaccharide conjugate vaccine (referred to as PCV13)PCV24 vaccine (dose H)PPV23 vaccinePCV24 vaccine (dose H)PCV13 vaccinePCV24 vaccine (dose M)PCV13 vaccinePCV24 vaccine (dose H)PCV13 vaccinePCV24 vaccine (dose L)PCV13 vaccinePCV24 vaccine (dose M)PCV13 vaccinePCV24 vaccine (dose H)PCV13 vaccinePCV24 vaccine (dose L or M or H)PPV23 vaccinePCV24 vaccine (dose L or M or H)PCV13 vaccine

24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (referred to as PCV24) (dose M): 1 dose ( 0.5ml) of PCV24 vaccine (dose M)

PCV24 vaccine (dose H): 1 dose ( 0.5ml) of PCV24 vaccine (dose H)

PCV24 vaccine (dose M): 1 dose ( 0.5ml) of PCV24 vaccine (dose M)

23-valent pneumococcal polysaccharide vaccine (referred to as PPV23): 1 dose ( 0.5ml) of PPV23 vaccine

PCV24 vaccine (dose M): 1 dose ( 0.5ml) of PCV24 vaccine (dose M)

13-valent pneumococcal polysaccharide conjugate vaccine (referred to as PCV13): 1 dose ( 0.5ml) of PCV13 vaccine

PCV24 vaccine (dose H): 1 dose ( 0.5ml) of PCV24 vaccine (dose H)

PPV23 vaccine: 1 dose ( 0.5ml) of PPV23 vaccine

PCV24 vaccine (dose H): 1 dose ( 0.5ml) of PCV24 vaccine (dose H)

PCV13 vaccine: 1 dose ( 0.5ml) of PCV13 vaccine

PCV24 vaccine (dose M): If trial participants are 12-23 months of age, they should receive 2 doses (0.5ml) of PCV24 ( dose M) , administered two months apart. If trial participants are 7-11 months of age, they should receive 2 doses ( 0.5ml) of PCV24 ( dose M) as a primary series, administered two months apart; a booster dose should be administered at 12-15 months of age, at least two months after the second dose.

PCV13 vaccine: If trial participants are 12-23 months of age, they should receive 2 doses (0.5ml) of PCV13, administered two months apart. If trial participants are 7-11 months of age, they should receive 2 doses ( 0.5ml) of PCV13 as a primary series, administered two months apart; a booster dose should be administered at 12-15 months of age, at least two months after the second dose.

PCV24 vaccine (dose H): If trial participants are 12-23 months of age, they should receive 2 doses ( 0.5ml) of PCV24 (dose H) , administered two months apart. If trial participants are 7-11 months of age, they should receive 2 doses ( 0.5ml) of PCV24 ( dose H) as a primary series, administered two months apart; a booster dose should be administered at 12-15 months of age, at least two months after the second dose.

PCV13 vaccine: If trial participants are 12-23 months of age, they should receive 2 doses ( 0.5ml) of PCV13 , administered two months apart. If trial participants are 7-11 months of age, they should receive 2 doses ( 0.5ml) of PCV13 as a primary series, administered two months apart; a booster dose should be administered at 12-15 months of age, at least two months after the second dose.

PCV24 vaccine (dose L): The primary vaccination series consists of 3 doses ( 0.5ml) of the PCV24 vaccine ( dose L) , administered 2 months apart; a single booster dose is administered at 12 to 15 months of age.

PCV13 vaccine: The primary vaccination series consists of 3 doses ( 0.5ml) of the PCV13 vaccine, administered 2 months apart; a single booster dose is administered at 12 to 15 months of age.

PCV24 vaccine (dose M): The primary vaccination series consists of 3 doses of the PCV24 vaccine ( 0.5ml) , administered 2 months apart; a single booster dose is administered at 12 to 15 months of age.

PCV13 vaccine: The primary vaccination series consists of 3 doses of the PCV13 vaccine ( 0.5ml) , administered 2 months apart; a single booster dose is administered at 12 to 15 months of age.

PCV24 vaccine (dose H): The primary vaccination series consists of 3 doses of the PCV24 vaccine ( 0.5ml) , administered 2 months apart; a single booster dose is administered at 12 to 15 months of age.

PCV13 vaccine: The primary vaccination series consists of 3 doses of the PCV13 vaccine ( 0.5ml) , administered 2 months apart; a single booster dose is administered at 12 to 15 months of age.

PCV24 vaccine (dose L or M or H): 1 dose ( 0.5ml) of PCV24 vaccine (dose L or M or H)

PPV23 vaccine: 1 dose ( 0.5ml) of PPV23 vaccine

PCV24 vaccine (dose L or M or H): A primary vaccination series consisting of 3 doses of the PCV24 vaccine ( 0.5ml) , with a 2-month interval between each dose; a single booster dose should be administered at 12 to 15 months of age.

PCV13 vaccine: A primary vaccination series consisting of 3 doses of the PCV13 vaccine ( 0.5ml) , with a 2-month interval between each dose; a single booster dose should be administered at 12 to 15 months of age.

Study summary

This clinical trial consists of Phase I and Phase II. The objective is to evaluate the safety and immunogenicity of the 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) in individuals aged 2 months (minimum 6 weeks) and older.

Eligibility

Sex

ALL

Min age

6 Weeks

Max age

—

Healthy volunteers

Accepted

Inclusion Criteria: Phase I: * Individuals aged 2 months (minimum 6 weeks), 7 months to 5 years, and 18 years and older who are willing to provide identification * The trial participant and/or guardian (legal representative) has voluntarily signed the informed consent form after providing informed consent * Children aged 5 and under who have not previously received a pneumococcal vaccine * People aged 18 and older who have not received a pneumonia vaccine in the past five years Phase II (age ≥50 group): * People aged 50 and older who are willing to provide identification documents * The trial participants voluntarily signed the informed consent form after providing their informed consent * People aged 50 and older who have not received a pneumonia vaccine in the past five years Phase II (2-month-old group (minimum 6 weeks)): * Individuals aged 2 months or older (minimum 6 weeks) who are willing to provide identification documents * The guardian (authorized representative) of the trial participant has voluntarily signed the informed consent form after providing informed consent. * Infants aged 2 months (minimum 6 weeks) who have not previously received a pneumococcal vaccine Exclusion Criteria: * Exclusion criteria for the first dose: * Preterm birth (delivery before 37 weeks of gestation), low birth weight (\<2500 g at birth), history of labor abnormalities or resuscitation due to asphyxia; (Applicable to individuals in Phase I and Phase II who are 2 months of age or older (minimum 6 weeks)) * Patients with abnormal results in pre-vaccination blood tests (including complete blood count, blood chemistry, and coagulation function) or urinalysis, which the investigator determines to be clinically significant; (Applicable only to Phase I participants aged 2 years (or 7 months) and older) * Individuals who are allergic to the active ingredient of the vaccine, any of its inactive ingredients, or substances used in the manufacturing process; or those who have previously experienced an allergic reaction after receiving a similar vaccine; Individuals with a history of severe allergic reactions to vaccines (such as acute allergic reactions, angioedema, or difficulty breathing), or a history of severe allergic reactions to any vaccine, food, or medication, including urticaria, anaphylactic shock, eczema, allergic respiratory distress, angioedema, or a history of asthma * Individuals with uncontrolled hypertension (as measured on-site: systolic blood pressure ≥160 mmHg and diastolic blood pressure ≥100 mmHg); (Applicable to Stage II participants aged 50 and older and Stage I participants aged 18 and older) * Women of childbearing age with a positive urine pregnancy test; participants who are breastfeeding; or participants or their partners who plan to become pregnant within the next 6 months; (Applicable to the Phase II group aged 50 or older and the Phase I group aged 18 or older) * History of epilepsy, seizures (excluding febrile seizures), convulsions, or brain disorders \[such as congenital brain malformations, traumatic brain injury, brain tumors, cerebral hemorrhage, cerebral infarction (excluding cerebral infarctions without sequelae and lacunar infarctions), brain infections, chemical poisoning, and other conditions causing damage to brain neural tissue\], or a history of mental illness or a family history thereof; or those with other progressive neurological diseases * Have been diagnosed with a congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), juvenile rheumatoid arthritis (JRA), or other autoimmune diseases * Known or suspected acute illness or severe chronic disease (including severe respiratory disease, severe cardiovascular disease, liver or kidney disease, severe skin disease, malignant tumors, etc.); or currently experiencing an acute exacerbation of a chronic condition * Clinically diagnosed coagulation disorders (such as coagulation factor deficiencies, coagulation disorders, or platelet abnormalities) or significant bruising or bleeding disorders * Asplenia, functional asplenia, and asplenia or splenectomy resulting from any cause * Patients who have received immunosuppressive therapy within 6 months prior to vaccination or who are scheduled to receive such therapy between enrollment and 1 month after completion of the vaccination series (e.g., long-term systemic corticosteroid use for ≥14 days at a dose \>2 mg/kg/day or ≥20 mg/day of prednisone or prednisone-equivalent dose) (excluding topical corticosteroids such as inhaled, nasal spray, intra-articular, eye drops, or ointments; topical use must not exceed the dose recommended in the product label or result in any signs of systemic exposure). Individuals who have used long-acting immunomodulatory drugs (e.g., infliximab) within 6 months prior to the first dose or who plan to use such drugs during the trial (applicable to the Phase II group aged ≥50 years and the Phase I group aged 7 months and older) * Received blood products (excluding hepatitis B immunoglobulin) within 3 months prior to receiving the investigational drug * Participation in any other clinical trial involving a drug or vaccine within the 6 months prior to enrollment, or currently participating in such a trial, or plans to participate in such a trial during the study period * Received an injectable live attenuated vaccine within 14 days prior to receiving the investigational drug, or received any other vaccine within 7 days * Underarm temperature of 37.3°C or higher prior to vaccination * According to the researchers' assessment, the trial participants had other factors that made them unsuitable for participation in the clinical trial Exclusion criteria for the 2nd, 3rd, and 4th doses: * Individuals who experienced a severe allergic reaction following the previous dose of the vaccine * Individuals who experienced a serious adverse reaction causally related to a previous dose of the vaccine * Other potential causes ruled out by the researchers

Primary outcome measure(s)

Phase I: Incidence of adverse reactions — Within 7 days of receiving each dose of the vaccine
Phase I: Incidence of adverse reactions — Within 30 days of receiving each dose of the vaccine
Phase I: Incidence of serious adverse event (SAE) — Within 180 days of receiving the first dose of the vaccine through completion of the full vaccination series for each group
Phase I: Incidence of abnormalities in urinalysis — 4 days after vaccination
Phase I: Incidence of abnormalities in complete blood count — 4 days after vaccination
Phase I: Incidence of abnormalities in blood chemistry — 4 days after vaccination
Phase I: Incidence of abnormalities in coagulation function — 4 days after vaccination
Phase II (≥50 years old group): Geometric mean concentration (GMC) of serotype-specific pneumococcal IgG antibodies — 30 days after vaccination
Phase II (≥50 years old group): ≥4-fold increase of serotype-specific pneumococcal IgG antibodies — 30 days after vaccination
Phase II (≥50 years old group): Geometric mean increment (GMI) of serotype-specific pneumococcal IgG antibodies — 30 days after vaccination
Phase II (≥50 years old group): Serotype-specific pneumococcal OPA antibody titers in some trial participants — 30 days after vaccination
Phase II (≥50 years old group): Proportion of trial participants with serotype-specific pneumococcal OPA antibody titers ≥1:8 — 30 days after vaccination
Phase II (≥50 years old group): Incidence of adverse reactions — Within 7 days of vaccination
Phase II (≥50 years old group): Incidence of adverse reactions — Within 30 days of vaccination
Phase II (2-month-old group [minimum 6 weeks]): Positive rate of vaccine-serotype-specific pneumococcal IgG antibodies (antibody concentration ≥ 0.35 μg/ml) — 30 days after the primary series, before the booster dose, and 30 days after the booster dose
Phase II (2-month-old group [minimum 6 weeks]): Proportion with vaccine-serotype-specific pneumococcal IgG antibody concentrations ≥ 1.0 μg/ml — 30 days after the primary series, before the booster dose, and 30 days after the booster dose
Phase II (2-month-old group [minimum 6 weeks]): GMC of serotype-specific pneumococcal IgG antibodies — 30 days after the primary series, before the booster dose, and 30 days after the booster dose
Phase II (2-month-old group [minimum 6 weeks]): GMI of serotype-specific pneumococcal IgG antibodies — 30 days after the primary series, before the booster dose, and 30 days after the booster dose
Phase II (2-month-old group [minimum 6 weeks]): Serotype-specific pneumococcal OPA antibody titers in some trial participants — 30 days after the primary series; 30 days after the booster dose
Phase II (2-month-old group [minimum 6 weeks]): Proportion of trial participants with serotype-specific pneumococcal OPA antibody titers ≥1:8 — 30 days after the primary series; 30 days after the booster dose
Phase II (2-month-old group [minimum 6 weeks]): Incidence of adverse reactions — Within 7 days of each dose
Phase II (2-month-old group [minimum 6 weeks]): Incidence of adverse reactions — Within 30 days of each dose

Trial sites (2)

Facility	City	Region	Status
Ningling County Center for Disease Control and Prevention	Shangqiu	China	Not Yet Recruiting
Xiangcheng County Center for Disease Control and Prevention	Xuchang	China	Recruiting

More CanSino Biologics Inc. trials in China

Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine Active, not recruiting

A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP) Active, not recruiting

Observation of Immune Persistence in a Clinical Trial of an Adsorbed Tetanus Vaccine Starting soon

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds Active, not recruiting

Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine Active, not recruiting

Other trials for the same condition

Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07600983 on ClinicalTrials.gov ↗ ← All trials in China